Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma

被引：7
作者：
Wang, Shuai [1 ]
Wu, Xuan [1 ]
Zhao, Jiuzhou [2 ]
Chen, Haiyang [1 ]
Zhang, Zhe [1 ]
Wang, Mingyue [1 ]
Xu, Cong [1 ]
Wang, Yongsen [2 ]
Wang, Lili [1 ]
He, Zhen [1 ]
Wang, Qiming [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China
[2] Zhengzhou Univ, Henan Canc Hosp, Dept Mol Pathol, Zhengzhou, Peoples R China
来源：
CLINICAL LUNG CANCER | 2021年 / 22卷 / 03期
基金：
中国国家自然科学基金;
关键词：
Crizotinib; Generation sequencin; Lung large-cell neuroendocrine carcinoma; PLB1-ALK; Sensitivity; ALK-REARRANGEMENT;
D O I：
10.1016/j.cllc.2020.05.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E366 / E370
页数：5
相关论文
共 11 条
  • [1] Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma
    He, Zhen
    Wu, Xuan
    Ma, Shuxiang
    Zhang, Cuicui
    Zhang, Zhe
    Wang, Shuai
    Yu, Sheng
    Wang, Qiming
    CLINICAL LUNG CANCER, 2019, 20 (05) : E548 - E551
  • [2] Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
    Zhou, Yuling
    Lizaso, Analyn
    Mao, Xinru
    Yang, Nong
    Zhang, Yongchang
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [3] Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing
    Xia, Yuxue
    Zhang, Lu
    He, Wenjuan
    Pan, Huaxiong
    Fang, Jun
    Cui, Guohui
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [4] ATAD2B-ALK, a Novel Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing (NGS)
    Bai, H.
    Jia, W.
    Jin, X.
    Mao, H.
    Wu, D.
    Chen, R.
    Xia, X.
    Wu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S844 - S844
  • [5] Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers
    Xia, Peiyi
    Zhang, Lan
    Li, Pan
    Liu, Enjie
    Li, Wencai
    Zhang, Jianying
    Li, Hui
    Su, Xiaoxing
    Jiang, Guozhong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [6] Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
    Zeng, Liang
    Li, Yizhi
    Xiao, Lili
    Xiong, Yi
    Liu, Li
    Jiang, Wenjuan
    Heng, Jianfu
    Qu, Jingjing
    Yang, Nong
    Zhang, Yongchang
    ONCOTARGETS AND THERAPY, 2018, 11 : 6937 - 6945
  • [7] A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
    Zhang, Min
    Zhou, Huan
    Liu, Dan
    Yu, Ruoying
    Chen, Jun
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (02):
  • [8] Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns
    Clave, Sergi
    Rodon, Natalia
    Pijuan, Lara
    Diaz, Olga
    Lorenzo, Marta
    Rocha, Pedro
    Taus, Alvaro
    Blanco, Remei
    Bosch-Barrera, Joaquim
    Reguart, Noemi
    de la Torre, Noelia
    Oliveras, Gloria
    Espinet, Blanca
    Bellosillo, Beatriz
    Puig, Xavier
    Arriola, Edurne
    Salido, Marta
    CLINICAL LUNG CANCER, 2019, 20 (04) : E421 - E429
  • [9] Molecular and clinicopathological characteristics ofROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing
    Cui, Meiying
    Han, Yuchen
    Li, Pan
    Zhang, Jianying
    Ou, Qiuxiang
    Tong, Xiaoling
    Zhao, Ruiying
    Dong, Nan
    Wu, Xue
    Li, Wencai
    Jiang, Guozhong
    MOLECULAR ONCOLOGY, 2020, 14 (11) : 2787 - 2795
  • [10] Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay
    Rodriguez-Antolin, Carlos
    Rosas-Alonso, Rocio
    Cruz, Patricia
    Higuera, Oliver
    Sanchez-Cabrero, Dario
    Esteban-Rodriguez, Isabel
    Pelaez-Garcia, Alberto
    Fernandez Montano, Victoria Eugenia
    Rodriguez-Jimenez, Carmen
    Ibanez de Caceres, Inmaculada
    de Castro, Javier
    ONCOLOGIST, 2021, 26 (06) : E908 - E912
12